Close Menu

NEW YORK (GenomeWeb) – Twist Bioscience and Pandion Therapeutics plan to use Twist's antibody optimization platform to develop therapeutics for autoimmune and inflammatory disease, the companies said today.

The firms did not disclose financial details of the agreement.

Twist "has a highly differentiated capability to optimize antibodies for many attributes including affinity, expression, solubility, half-life, immunogenicity, druggability, and processability," Anthony Coyle, co-founder and CEO of Pandion, said in a statement.

To read the full story....

...and receive Daily News bulletins.

Already have a GenomeWeb or 360Dx account?
Login Now.

The New York Times Magazine examines gender discrimination at the Salk Institute.

Science reports that MD Anderson Cancer Center has dismissed three researchers over foreign tie concerns.

A second death in gene therapy trial for type 1 spinal muscular atrophy is under investigation, according to Reuters.

In PLOS this week: antibiotic resistance patterns in Escherichia coli, a dozen genetic loci tied to varicose vein risk, and more.